Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 201 participants.
Also called NCT01452815
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 201 participants
- Sponsor
- Tranzyme, Inc.
- Registry
-
NCT01452815
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Belgium, Denmark, Finland, Germany, Norway, Poland, Sweden
- Registry status
- Completed
Technical summary
Registry record NCT01452815. Randomized; quadruple masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2012-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
- Condition
- Gastroparesis
- Condition
- Diabetes Mellitus, Type 1
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- 10mg TZP-102
- Intervention (Drug)
- 20mg TZP-102
- Lead sponsor
- Tranzyme, Inc.
Record details
- Record id
cardio:ct-nct01452815- Content hash
1beca1760016de97b569dfb5e31100d963e26b0f6b144a151e616f63eb147d05